Natco Pharma Limited — Investor Meet, 14-11-2025: Analysts/Institutional Investor Meet/Con. Call Updates

NATCO Pharma's Q2FY26 consolidated revenue hit 1,463 Cr. Pharma Export Formulations contributed 1,147 Cr, with Domestic Formulations at 105.4 Cr. EBITDA stood at 679.2 Cr (46.4% margin) and PAT at 517.9 Cr (35.4% margin), showing a decline from Q2FY25. EPS was INR 28.94. The company held 3,903 Cr in net cash. Strategic focus remains on its robust US pipeline with over 20 Para IV First-To-File opportunities and significant investments in NCE, cell, and gene therapy ventures like eGenesis and Cellogen Therapeutics, highlighting future growth drivers.